Cargando…

Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens

Attenuated vaccinia virus (VACV) vectors are considered prime vaccine candidates for use in immunotherapy of infectious disease. In spite of this, recent data show that the level of attenuation may hamper the efficient generation of protective CD8 T cells. This suggests that additional adjuvant-like...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yuan, Tahiliani, Vikas, Salek-Ardakani, Shahram, Croft, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492829/ https://www.ncbi.nlm.nih.gov/pubmed/23162550 http://dx.doi.org/10.3389/fimmu.2012.00332

Ejemplares similares

OX40:OX40L axis: emerging targets for improving poxvirus‐based CD8(+) T‐cell vaccines against respiratory viruses
por: Goulding, John, et al.
Publicado: (2011)

Transcription Factor Bcl11b Controls Effector and Memory CD8 T cell Fate Decision and Function during Poxvirus Infection
por: Abboud, Georges, et al.
Publicado: (2016)

Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications
por: Salek-Ardakani, Shahram, et al.
Publicado: (2023)

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
por: Zapata, Juan M., et al.
Publicado: (2018)

Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
por: Liu, Guizhong, et al.
Publicado: (2023)

CD8(+) T Cell Exhaustion in Cancer
por: Dolina, Joseph S., et al.
Publicado: (2021)

EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8(+) T Cells
por: Stairiker, Christopher J., et al.
Publicado: (2021)

EZH2 as a Regulator of CD8+ T Cell Fate and Function
por: Stairiker, Christopher J., et al.
Publicado: (2020)

CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer
por: Yi, Ling, et al.
Publicado: (2022)

Tissue-specific programming of memory CD8 T cell subsets impacts protection against lethal respiratory virus infection
por: Abboud, Georges, et al.
Publicado: (2016)

Staining of activated ß(2)-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4(+) and CD8(+) T cells
por: Schöllhorn, Anna, et al.
Publicado: (2023)

4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)

CD8 T Cell Memory to a Viral Pathogen Requires Trans Cosignaling between HVEM and BTLA
por: Flynn, Rachel, et al.
Publicado: (2013)

The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity
por: Choi, Beom K., et al.
Publicado: (2020)

A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors
por: Konstorum, Anna, et al.
Publicado: (2019)

TCR-independent CD137 (4–1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation
por: Pichler, Andrea C., et al.
Publicado: (2023)

Identification of CD137-Expressing B Cells in Multiple Sclerosis Which Secrete IL-6 Upon Engagement by CD137 Ligand
por: Wong, Hiu Yi, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
por: Otano, Itziar, et al.
Publicado: (2021)

CD137-CD137 Ligand Interactions in Inflammation
por: Kwon, Byungsuk
Publicado: (2009)

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation
por: Halim, Leena, et al.
Publicado: (2022)

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
por: Vinay, Dass S., et al.
Publicado: (2014)

Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection
por: Jofra, Tatiana, et al.
Publicado: (2017)

Adaptive Memory of Human NK-like CD8(+) T-Cells to Aging, and Viral and Tumor Antigens
por: Pita-López, María Luisa, et al.
Publicado: (2016)

4-1BB (CD137) and radiation therapy: A case report and literature review
por: Shiao, Jay C., et al.
Publicado: (2017)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy
por: Steel, Helen C., et al.
Publicado: (2021)

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives
por: Zeng, Qun, et al.
Publicado: (2019)

CD8(+) Resident Memory T Cells and Viral Infection
por: Wu, Xuejie, et al.
Publicado: (2018)

CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity
por: Stoll, A., et al.
Publicado: (2021)

Splicing factor SRSF1 is essential for CD8 T cell function and host antigen-specific viral immunity
por: Juarez, Ignacio, et al.
Publicado: (2022)

CD8αα Expression Marks Terminally Differentiated Human CD8+ T Cells Expanded in Chronic Viral Infection
por: Walker, L. J., et al.
Publicado: (2013)

Deletion of CD137 Ligand Exacerbates Renal and Cutaneous but Alleviates Cerebral Manifestations in Lupus
por: Mak, Anselm, et al.
Publicado: (2019)

Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs
por: Zeng, Qun, et al.
Publicado: (2019)

Soluble CD137 Ameliorates Acute Type 1 Diabetes by Inducing T Cell Anergy
por: Itoh, Arata, et al.
Publicado: (2019)

CD169 Defines Activated CD14(+) Monocytes With Enhanced CD8(+) T Cell Activation Capacity
por: Affandi, Alsya J., et al.
Publicado: (2021)

Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
por: Upadhyaya, Punit, et al.
Publicado: (2021)

CpG Oligodeoxinucleotides and Flagellin Modulate the Immune Response to Antigens Targeted to CD8α(+) and CD8α(−) Conventional Dendritic Cell Subsets
por: Antonialli, Renan, et al.
Publicado: (2017)

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
por: Chen, Siqi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s2cc6bmpri0ep3vofkptg41s3b